Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Vallet

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Expert Opinion on Pharmacotherapy|February 14, 2012
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignanciesSonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, et al.
Pharmaceutics|October 26, 2018
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment StrategiesSonia Vallet, Julia-Marie Filzmoser, Martin Pecherstorfer, et al.
Expert Opinion on Therapeutic Targets|March 23, 2025
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapyRajeshwari Meli, Osman Aksoy, Sonia Vallet, et al.
Cytokine|November 4, 2022
Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implicationsOsman Aksoy, Judith Lind, Vincent Sunder-Plaßmann, et al.
Leukemia & Lymphoma|May 3, 2008
Thalidomide and lenalidomide: Mechanism-based potential drug combinationsSonia Vallet, Antonio Palumbo, Noopur Raje, et al.
Expert Opinion on Investigational Drugs|April 10, 2019
Targeting transcription factors in multiple myeloma: evolving therapeutic strategiesShirong Li, Sonia Vallet, Antonio Sacco, et al.
Leukemia & Lymphoma|January 19, 2018
A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myelomaSonia Vallet, Nicholas R Hoyle, Robert A Kyle, et al.
Expert Opinion on Pharmacotherapy|July 13, 2022
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the futureVincent Sunder-Plassmann, Osman Aksoy, Judith Lind, et al.
Expert Opinion on Emerging Drugs|March 3, 2009
Emerging therapies for multiple myelomaKlaus Podar, Yu-Tzu Tai, Teru Hideshima, et al.
Investigational New Drugs|May 20, 2015
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasisSarah Schott, Sonia Vallet, Robert J Tower, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Expert Opinion on Pharmacotherapy|February 14, 2012
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignanciesSonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, et al.
Pharmaceutics|October 26, 2018
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment StrategiesSonia Vallet, Julia-Marie Filzmoser, Martin Pecherstorfer, et al.
Expert Opinion on Therapeutic Targets|March 23, 2025
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapyRajeshwari Meli, Osman Aksoy, Sonia Vallet, et al.
Cytokine|November 4, 2022
Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implicationsOsman Aksoy, Judith Lind, Vincent Sunder-Plaßmann, et al.
Leukemia & Lymphoma|May 3, 2008
Thalidomide and lenalidomide: Mechanism-based potential drug combinationsSonia Vallet, Antonio Palumbo, Noopur Raje, et al.
Expert Opinion on Investigational Drugs|April 10, 2019
Targeting transcription factors in multiple myeloma: evolving therapeutic strategiesShirong Li, Sonia Vallet, Antonio Sacco, et al.
Leukemia & Lymphoma|January 19, 2018
A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myelomaSonia Vallet, Nicholas R Hoyle, Robert A Kyle, et al.
Expert Opinion on Pharmacotherapy|July 13, 2022
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the futureVincent Sunder-Plassmann, Osman Aksoy, Judith Lind, et al.
Expert Opinion on Emerging Drugs|March 3, 2009
Emerging therapies for multiple myelomaKlaus Podar, Yu-Tzu Tai, Teru Hideshima, et al.
Investigational New Drugs|May 20, 2015
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasisSarah Schott, Sonia Vallet, Robert J Tower, et al.
Pageof 8